bluebird bio Inc (NAS:BLUE)
$ 0.4171 0.0121 (2.99%) Market Cap: 81.10 Mil Enterprise Value: 376.50 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 31/100

bluebird bio Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript

May 14, 2020 / 02:20PM GMT
Release Date Price: $35 (-3.15%)
Jason Matthew Gerberry;Nick Leschly
BofA Merrill Lynch, Research Division - MD in US Equity Research;bluebird bio, Inc. - President, CEO &

Good day, everybody, and thank you for joining us at the Bank of America Virtual Health Care Conference. My name is Jason Gerberry. I cover SMID cap biotech at BofA, and I am pleased to be introducing our next company presenter, bluebird bio. We're joined by Nick Leschly, CEO, and several members of the management team will also be dialing into the call as well.

So bluebird bio is focused on developing complex and potentially curative therapies for underserved populations. I'd argue the company's gene and cell therapies are still in the relative early innings as a therapeutic modality, and blue is one of the pioneers looking to blaze a trail for these therapies and work through some logistical and technical challenges in bringing these new therapeutic modalities to market.

And so pleased to be introducing the company, and Nick has some initial prepared remarks, and then we'll jump into Q&A. So Nick, all yours.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot